|
|
 Previous Article | Table of Contents | Next Article 
RAPID COMMUNICATION
Gene Therapy for Chronic Myelogenous Leukemia (CML): A Retroviral Vector That Renders Hematopoietic Progenitors Methotrexate-Resistant and CML Progenitors Functionally Normal and Nontumorigenic In Vivo
Robert C.H. Zhao,
R. Scott McIvor,
James D. Griffin, and
Catherine M. Verfaillie
From the Stem Cell Biology Program, Department of Medicine and Institute of Human Genetics and Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN; and the Department of Medicine, Dana-Farber Cancer Institute, Boston, MA.
Chronic myelogenous leukemia (CML) is a malignant disease of the human hematopoietic stem cell caused by the BCR/ABL gene rearrangement. The only curative therapy is allogeneic transplantation. Although autologous transplants may prolong survival, most patients relapse because of disease persisting in the host and in the graft. Continued administration of chemotherapy after transplant could reduce the incidence of relapse provided that the autograft can be protected by transfer of a drug-resistance gene. However, CML autografts will almost certainly contain malignant stem cells that will also be rendered drug-resistant. The presence of the BCR/ABL oncoprotein is necessary and sufficient for malignant transformation seen in CML. We thus hypothesized that transfer of a vector that combines a drug-resistance gene with anti-BCR/ABL antisense (AS) sequences may allow for posttransplant chemotherapy to decrease persistent disease while rendering inadvertently transduced CML stem and progenitor cells functionally normal. We constructed a retroviral vector, LasBD, that combines the methotrexate (MTX)-resistant tyrosine-22 dihydrofolate-reductase (tyr22-DHFR) gene and AS sequences directed at the b3a2 BCR/ABL breakpoint. b3a2 BCR/ABL containing 32D and MO7e cells were transduced with LasBD and selected in MTX for 14 days. Expression of the AS sequences reduced BCR/ABL mRNA and p210BCR/ABL protein levels by 6- to 10-fold in most cells. This subsequently led to the restoration of normal function of BCR/ABL cDNA+ cells: they grew significantly slower in the presence of interleukin-3 (IL-3); they underwent apoptotic cell death when cultured without IL-3; and they had restored expression and function of adhesion receptors. These effects were specific, because LasBD-containing AS sequences directed at the b3a2 BCR/ABL breakpoint did not affect p190BCR/ABL-containing cells. LasBD also rendered 20% to 30% of primary Ph- and Ph+ CD34+ cells MTX-resistant and decreased BCR/ABL mRNA levels in MTX resistant Ph+ CD34+ cells by 10-fold. Expression of the MTX-resistant DHFR gene and the AS sequences has been stable for at least 1 year in vitro and for more than 70 days in vivo. Finally, LasBD decreased tumorigenicity of 32DBCR/ABL cells in vivo by 3 to 4 logs. In conclusion, the tyr22-DHFR gene in the LasBD vector can protect normal hematopoietic cells from MTX-mediated toxicity, whereas the AS sequences in LasBD can suppress expression of the BCR/ABL gene and restore normal function of BCR/ABL cDNA-containing cells. The LasBD vector may therefore prove to be an extremely useful adjunct in autologous transplantation for CML.
Blood, Vol. 90 No. 12 (December 15), 1997:
pp. 4687-4698
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. L. Gori, K. Podetz-Pedersen, D. Swanson, A. D. Karlen, R. Gunther, N. V. Somia, and R. S. McIvor
Protection of Mice from Methotrexate Toxicity by ex Vivo Transduction Using Lentivirus Vectors Expressing Drug-Resistant Dihydrofolate Reductase
J. Pharmacol. Exp. Ther.,
September 1, 2007;
322(3):
989 - 997.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. C. Matte, J. Cormier, B. E. Anderson, I. Athanasiadis, J. Liu, S. G. Emerson, W. Pear, and W. D. Shlomchik
Graft-versus-leukemia in a retrovirally induced murine CML model: mechanisms of T-cell killing
Blood,
June 1, 2004;
103(11):
4353 - 4361.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. L. Sweeney, J. L. Frandsen, C. M. Verfaillie, and R. S. McIvor
Trimetrexate Inhibits Progression of the Murine 32Dp210 Model of Chronic Myeloid Leukemia in Animals Expressing Drug-resistant Dihydrofolate Reductase
Cancer Res.,
March 15, 2003;
63(6):
1304 - 1310.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. L. Sweeney, M. D. Diers, J. L. Frandsen, R. Gunther, C. M. Verfaillie, and R. S. McIvor
Methotrexate Exacerbates Tumor Progression in a Murine Model of Chronic Myeloid Leukemia
J. Pharmacol. Exp. Ther.,
March 1, 2002;
300(3):
1075 - 1084.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Zaucha, C. Yu, G. Mathioudakis, K. Seidel, G. Georges, G. Sale, M.-T. Little, B. Torok-Storb, and R. Storb
Hematopoietic responses to stress conditions in young dogs compared with elderly dogs
Blood,
July 15, 2001;
98(2):
322 - 327.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. C. Zhao, Y. Jiang, and C. M. Verfaillie
A model of human p210bcr/ABL-mediated chronic myelogenous leukemia by transduction of primary normal human CD34+ cells with a BCR/ABL-containing retroviral vector
Blood,
April 15, 2001;
97(8):
2406 - 2412.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K.-Y. Jen and A. M. Gewirtz
Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies
Stem Cells,
September 1, 2000;
18(5):
307 - 319.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
C. Cobaleda and I. Sanchez-Garcia
In vivo inhibition by a site-specific catalytic RNA subunit of RNase P designed against the BCR-ABL oncogenic products: a novel approach for cancer treatment
Blood,
February 1, 2000;
95(3):
731 - 737.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Jiang, F. Prosper, and C. M. Verfaillie
Opposing effects of engagement of integrins and stimulation of cytokine receptors on cell cycle progression of normal human hematopoietic progenitors
Blood,
February 1, 2000;
95(3):
846 - 854.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Gewirtz, D. L. Sokol, and M. Z. Ratajczak
Nucleic Acid Therapeutics: State of the Art and Future Prospects
Blood,
August 1, 1998;
92(3):
712 - 736.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Bhatia and C. M. Verfaillie
Inhibition of BCR-ABL Expression With Antisense Oligodeoxynucleotides Restores beta 1 Integrin-Mediated Adhesion and Proliferation Inhibition in Chronic Myelogenous Leukemia Hematopoietic Progenitors
Blood,
May 1, 1998;
91(9):
3414 - 3422.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
